Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19 : analysis of the nationwide BSMO-COVID registry providing lessons for the future
Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Solid cancer is an independent prognostic factor for poor outcome with COVID-19. As guidelines for patient management in that setting depend on retrospective efforts, we here present the first analyses of a nationwide database of patients with cancer hospitalized with COVID-19 in Belgium, with a focus on changes in anticancer treatment plans at the time of SARS-CoV-2 infection.
METHODS: Nineteen Belgian hospitals identified all patients with a history of solid cancer hospitalized with COVID-19 between March 2020 and February 2021. Demographic, cancer-specific and COVID-specific data were pseudonymously entered into a central Belgian Society of Medical Oncology (BSMO)-COVID database. The association between survival and primary cancer type was analyzed through multivariate multinomial logistic regression. Group comparisons for categorical variables were carried out through a Chi-square test.
RESULTS: A total of 928 patients were registered in the database; most of them were aged ≥70 years (61.0%) and with poor performance scores [57.2% Eastern Cooperative Oncology Group (ECOG) ≥2]. Thirty-day COVID-related mortality was 19.8%. In multivariate analysis, a trend was seen for higher mortality in patients with lung cancer (27.6% versus 20.8%, P = 0.062) and lower mortality for patients with breast cancer (13.0% versus 23.3%, P = 0.052) compared with other tumour types. Non-curative treatment was associated with higher 30-day COVID-related mortality rates compared with curative or no active treatment (25.8% versus 14.3% versus 21.9%, respectively, P < 0.001). In 33% of patients under active treatment, the therapeutic plan was changed due to COVID-19 diagnosis, most frequently involving delays/interruptions in systemic treatments (18.6%). Thirty-day COVID-related mortality was not significantly different between patients with and without treatment modifications (21.4% versus 20.5%).
CONCLUSION: Interruption in anticancer treatments at the time of SARS-CoV-2 infection was not associated with a reduction in COVID-related mortality in our cohort of patients with solid cancer, highlighting that treatment continuation should be strived for, especially in the curative setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
ESMO open - 7(2022), 6 vom: 20. Dez., Seite 100610 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Geukens, T [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 27.12.2022 Date Revised 03.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.esmoop.2022.100610 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348700075 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348700075 | ||
| 003 | DE-627 | ||
| 005 | 20231226040857.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2022.100610 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM348700075 | ||
| 035 | |a (NLM)36356416 | ||
| 035 | |a (PII)S2059-7029(22)00241-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Geukens, T |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19 |b analysis of the nationwide BSMO-COVID registry providing lessons for the future |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.12.2022 | ||
| 500 | |a Date Revised 03.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Solid cancer is an independent prognostic factor for poor outcome with COVID-19. As guidelines for patient management in that setting depend on retrospective efforts, we here present the first analyses of a nationwide database of patients with cancer hospitalized with COVID-19 in Belgium, with a focus on changes in anticancer treatment plans at the time of SARS-CoV-2 infection | ||
| 520 | |a METHODS: Nineteen Belgian hospitals identified all patients with a history of solid cancer hospitalized with COVID-19 between March 2020 and February 2021. Demographic, cancer-specific and COVID-specific data were pseudonymously entered into a central Belgian Society of Medical Oncology (BSMO)-COVID database. The association between survival and primary cancer type was analyzed through multivariate multinomial logistic regression. Group comparisons for categorical variables were carried out through a Chi-square test | ||
| 520 | |a RESULTS: A total of 928 patients were registered in the database; most of them were aged ≥70 years (61.0%) and with poor performance scores [57.2% Eastern Cooperative Oncology Group (ECOG) ≥2]. Thirty-day COVID-related mortality was 19.8%. In multivariate analysis, a trend was seen for higher mortality in patients with lung cancer (27.6% versus 20.8%, P = 0.062) and lower mortality for patients with breast cancer (13.0% versus 23.3%, P = 0.052) compared with other tumour types. Non-curative treatment was associated with higher 30-day COVID-related mortality rates compared with curative or no active treatment (25.8% versus 14.3% versus 21.9%, respectively, P < 0.001). In 33% of patients under active treatment, the therapeutic plan was changed due to COVID-19 diagnosis, most frequently involving delays/interruptions in systemic treatments (18.6%). Thirty-day COVID-related mortality was not significantly different between patients with and without treatment modifications (21.4% versus 20.5%) | ||
| 520 | |a CONCLUSION: Interruption in anticancer treatments at the time of SARS-CoV-2 infection was not associated with a reduction in COVID-related mortality in our cohort of patients with solid cancer, highlighting that treatment continuation should be strived for, especially in the curative setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a prognosis | |
| 650 | 4 | |a solid tumours | |
| 650 | 4 | |a treatment changes | |
| 700 | 1 | |a Brandão, M |e verfasserin |4 aut | |
| 700 | 1 | |a Laenen, A |e verfasserin |4 aut | |
| 700 | 1 | |a Collignon, J |e verfasserin |4 aut | |
| 700 | 1 | |a Van Marcke, C |e verfasserin |4 aut | |
| 700 | 1 | |a Louviaux, I |e verfasserin |4 aut | |
| 700 | 1 | |a Demey, W |e verfasserin |4 aut | |
| 700 | 1 | |a Van Wambeke, S |e verfasserin |4 aut | |
| 700 | 1 | |a Schrijvers, D |e verfasserin |4 aut | |
| 700 | 1 | |a Lecomte, S |e verfasserin |4 aut | |
| 700 | 1 | |a Mebis, J |e verfasserin |4 aut | |
| 700 | 1 | |a Rutten, A |e verfasserin |4 aut | |
| 700 | 1 | |a Fontaine, C |e verfasserin |4 aut | |
| 700 | 1 | |a Lybaert, W |e verfasserin |4 aut | |
| 700 | 1 | |a Aspeslagh, S |e verfasserin |4 aut | |
| 700 | 1 | |a Goeminne, J-C |e verfasserin |4 aut | |
| 700 | 1 | |a Van Den Bulck, H |e verfasserin |4 aut | |
| 700 | 1 | |a Seront, E |e verfasserin |4 aut | |
| 700 | 1 | |a De Backer, L |e verfasserin |4 aut | |
| 700 | 1 | |a De Roock, W |e verfasserin |4 aut | |
| 700 | 1 | |a Ignatiadis, M |e verfasserin |4 aut | |
| 700 | 1 | |a Prenen, H |e verfasserin |4 aut | |
| 700 | 1 | |a Van Beckhoven, D |e verfasserin |4 aut | |
| 700 | 1 | |a Heijlen, M |e verfasserin |4 aut | |
| 700 | 1 | |a Verheezen, J |e verfasserin |4 aut | |
| 700 | 1 | |a Rottey, S |e verfasserin |4 aut | |
| 700 | 1 | |a Punie, K |e verfasserin |4 aut | |
| 700 | 1 | |a de Azambuja, E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d 2016 |g 7(2022), 6 vom: 20. Dez., Seite 100610 |w (DE-627)NLM266189539 |x 2059-7029 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2022 |g number:6 |g day:20 |g month:12 |g pages:100610 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.esmoop.2022.100610 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2022 |e 6 |b 20 |c 12 |h 100610 | ||